1.Effect of SiO2 nanoparticles exposure on microRNA expression level in human bronchial epithelial cells.
Yarui YANG ; Yun HE ; Chunmei GONG ; Jichang ZHOU ; Yumei ZHU ; Junluan MO
Chinese Journal of Preventive Medicine 2016;50(3):244-249
OBJECTIVETo investigate the effect of short and long term exposure to SiO2 nanoparticles on microRNA expression level in human bronchial epithelial cells(16HBE cells).
METHODSThe 16HBE cells were exposed to 5, 10, 15, 20, 25, 30 and 40 μg/ml SiO2 nanoparticles for 24 h to detect the cell viability by using CCK-8 assay. The inhibition rate of proliferation activity and half inhibitory concentration (IC50) were calculated. The 16HBE cells were exposed to 10 μg/ml SiO2 nanoparticles for 10 and 30 generations, named P10 and P30, and the control P0 was set. The cells were treated with SiO2 nanoparticles at 0, 1/4 IC50, 1/2 IC50 and IC50 concentration and μm-SiO2 at IC50 concentration for 24 h, and the control serum-free culture medium was set. Agilent miRNAs microarray chip was used to screen differentially expressed miRNAs in P10, P30 and P0 groups. The expression level of miRNA was detected by reverse transcription fluorescence quantitative polymerase chain reaction (qRT-PCR).
RESULTSThe inhibition rate of proliferation activity of 5, 10, 15, 20, 25,30,40 μg/ml group were (-3.33 ± 3.80)%, (20.40 ± 11.73)%, (39.08 ± 5.53)%, (55.10 ± 5.78)%, (66.42 ± 9.60)%, (71.67 ± 7.34)%, (81.43 ± 5.37)%, respectively; F=129.11, P<0.001. The IC50 (95%CI) was 18.35 (15.82-20.72) μg/ml. The expression level of miRNA-494-3p in P0, P10 and P30 were 1.00, 0.45 ± 0.08, 0.28 ± 0.07, respectively; F=60.77, P<0.001. miRNA-19a-3p were 1.00, 2.27 ± 0.45, 1.06 ± 0.19, respectively; F=30.05, P<0.001. miRNA-148b-3p were 1.00, 1.78 ± 0.29, 0.88 ± 0.19, respectively; F=30.23, P<0.001. Compared to control group, the expression level of miRNA-494-3p in 5, 10, 20 μg/ml SiO2 nanoparticles groups and 20 μg/ml μm-SiO2 group were 0.99 ± 0.04, 1.38 ± 0.19, 2.13 ± 0.14, 0.81 ± 0.25, respectively; F=57.03, P<0.001. miRNA-19a-3p were 0.91 ± 0.03, 1.12 ± 0.03, 0.53 ± 0.01, 0.86 ± 0.01, respectively; F=408.78, P<0.001. miRNA-148b-3p were 0.95 ± 0.02, 1.22 ± 0.00, 0.54 ± 0.02, 1.15 ± 0.04 respectively; F=264.14, P<0.001.
CONCLUSIONShort and long term exposure to SiO2 nanoparticles can affect the expression level of miRNAs in 16HBE cells. The expressions of miRNA-494-3p after long and short period exposure are different.
Cells, Cultured ; Epithelial Cells ; drug effects ; metabolism ; Humans ; MicroRNAs ; metabolism ; Nanoparticles ; chemistry ; Oligonucleotide Array Sequence Analysis ; Silicon Dioxide ; chemistry
2.Current situation of knowledge related to Kngaroo Mother Care among neonatal intensive care unit nurses
Yarui MO ; Shuju FENG ; Yajing WANG ; Haiyang LI ; Qian ZHANG
Chinese Journal of Practical Nursing 2020;36(20):1565-1569
Objective:To investigate the current Kangaroo Mother Care(KMC) knowledge among registered nurses working in neonatal intensive care unit (NICU) in China.Methods:A convenience sample of 607 registered nurses participated in this descriptive, cross sectional exploratory study. An online self-designed questionnaire was used to collect the data, including 12 items, 3 sections (Basic knowledge, Emergency handling, Breast feeding).Results:The total score was 6.52±2.29 (the total score was 12). The 5 items, accuracy below 50%, were ①In your opinion, the optimal duration of KMC was (10.2%,62/607); ②What to do if the baby had respiratory arrest or became blue during KMC (18.8%,114/607); ③Who should implement KMC (42.5%, 258/607); ④what could we do if the baby was not gaining weight (47.3%, 287/607); ⑤How to feed the baby during KMC (47.8%, 290/607). Registered nurses with more than 10 years of working experience in NICU scored higher; junior registered nurses scored lower; registered nurses learned by individuals scored lower ( F values were 9.413, 9.862, 5.368, all P<0.01). Conclusions:The insufficiency of KMC knowledge is common among NICU registered nurses. The understanding of basic concepts of KMC should be strengthened. Stratified training should be conducted for nurses′ ability to deal with emergencies, assess the changes in infants' conditions, and knowledge of breast feeding. All registered nurses′ KMC operation should be standardized to improve the level of implementation of KMC by NICU registered nurses.
3.GDF15 negatively regulates chemosensitivity via TGFBR2-AKT pathway-dependent metabolism in esophageal squamous cell carcinoma.
Yingxi DU ; Yarui MA ; Qing ZHU ; Yong FU ; Yutong LI ; Ying ZHANG ; Mo LI ; Feiyue FENG ; Peng YUAN ; Xiaobing WANG
Frontiers of Medicine 2023;17(1):119-131
Treating patients with esophageal squamous cell carcinoma (ESCC) is challenging due to the high chemoresistance. Growth differentiation factor 15 (GDF15) is crucial in the development of various types of tumors and negatively related to the prognosis of ESCC patients according to our previous research. In this study, the link between GDF15 and chemotherapy resistance in ESCC was further explored. The relationship between GDF15 and the chemotherapy response was investigated through in vitro and in vivo studies. ESCC patients with high levels of GDF15 expression showed an inferior chemotherapeutic response. GDF15 improved the tolerance of ESCC cell lines to low-dose cisplatin by regulating AKT phosphorylation via TGFBR2. Through an in vivo study, we further validated that the anti-GDF15 antibody improved the tumor inhibition effect of cisplatin. Metabolomics showed that GDF15 could alter cellular metabolism and enhance the expression of UGT1A. AKT and TGFBR2 inhibition resulted in the reversal of the GDF15-induced expression of UGT1A, indicating that TGFBR2-AKT pathway-dependent metabolic pathways were involved in the resistance of ESCC cells to cisplatin. The present investigation suggests that a high level of GDF15 expression leads to ESCC chemoresistance and that GDF15 can be targeted during chemotherapy, resulting in beneficial therapeutic outcomes.
Humans
;
Esophageal Squamous Cell Carcinoma/drug therapy*
;
Cisplatin/metabolism*
;
Esophageal Neoplasms/metabolism*
;
Proto-Oncogene Proteins c-akt/metabolism*
;
Carcinoma, Squamous Cell/genetics*
;
Growth Differentiation Factor 15/therapeutic use*
;
Receptor, Transforming Growth Factor-beta Type II/therapeutic use*
;
Cell Line, Tumor
;
Cell Proliferation
;
Gene Expression Regulation, Neoplastic